KalVista Pharmaceuticals (KALV) Prepaid Assets (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Prepaid Assets of $1.5 million in Q3 2025, down 92.61% quarter-over-quarter from $19.7 million in Q2 2025, and down 52.67% year-over-year from $3.1 million in Q3 2024.
KalVista Pharmaceuticals' Prepaid Assets history runs 12 years deep, the most recent figure standing at $1.5 million for Q3 2025.
- In Q3 2025, Prepaid Assets fell 52.67% year-over-year to $1.5 million; the TTM figure through Jul 2025 stood at $1.5 million (down 52.67% YoY), while the FY2025 annual figure was $19.7 million, up 595.02% from the prior year.
- Prepaid Assets came in at $1.5 million for Q3 2025 at KalVista Pharmaceuticals, down from $19.7 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $19.7 million in Q2 2025 to a low of $1.5 million in Q3 2025.
- A 5-year average of $5.8 million and a median of $4.9 million in 2021 frame the typical range for Prepaid Assets.
- Across the five-year window, Prepaid Assets slumped 80.0% in 2023 and soared 595.02% in 2025, its largest moves.
- KalVista Pharmaceuticals' Prepaid Assets stood at $7.3 million in 2021, then climbed by 22.68% to $8.9 million in 2022, then plunged by 80.0% to $1.8 million in 2023, then surged by 248.68% to $6.2 million in 2024, then tumbled by 76.6% to $1.5 million in 2025.
- According to Business Quant data, Prepaid Assets over the past three periods registered $1.5 million, $19.7 million, and $6.2 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 1.46 Mn |
| Apr 30, 2025 | 19.69 Mn |
| Dec 31, 2024 | 6.22 Mn |
| Oct 31, 2024 | 5.41 Mn |
| Jul 31, 2024 | 3.07 Mn |
| Apr 30, 2024 | 2.83 Mn |
| Jan 31, 2024 | 2.96 Mn |
| Oct 31, 2023 | 1.78 Mn |
| Jul 31, 2023 | 2.84 Mn |
| Apr 30, 2023 | 2.58 Mn |
| Jan 31, 2023 | 2.52 Mn |
| Oct 31, 2022 | 8.91 Mn |
| Jul 31, 2022 | 11.08 Mn |
| Apr 30, 2022 | 8.40 Mn |
| Jan 31, 2022 | 8.39 Mn |
| Oct 31, 2021 | 7.27 Mn |
| Jul 31, 2021 | 5.54 Mn |
| Apr 30, 2021 | 4.92 Mn |
| Jan 31, 2021 | 4.60 Mn |
| Oct 31, 2020 | 1.52 Mn |
| Jul 31, 2020 | 3.26 Mn |
| Apr 30, 2020 | 4.46 Mn |
| Jan 31, 2020 | 3.63 Mn |
| Oct 31, 2019 | 2.62 Mn |
| Jul 31, 2019 | 2.73 Mn |
| Apr 30, 2019 | 3.42 Mn |
| Jan 31, 2019 | 3.95 Mn |
| Oct 31, 2018 | 1.92 Mn |
| Jul 31, 2018 | 1.51 Mn |
| Apr 30, 2018 | 1.49 Mn |
| Jan 31, 2018 | 2.00 Mn |
| Oct 31, 2017 | 1.40 Mn |
| Jul 31, 2017 | 841,000.00 |
| Apr 30, 2017 | 701,000.00 |
| Jan 31, 2017 | 1.22 Mn |
| Mar 31, 2016 | 1.01 Mn |
| Dec 31, 2015 | 1.22 Mn |
| Sep 30, 2015 | 1.57 Mn |
| Jun 30, 2015 | 1.61 Mn |
| Mar 31, 2015 | 1.13 Mn |
| Dec 31, 2014 | 690,000.00 |